Peer-reviewed industrial hemp research papers, sorted by publication date. Browse the latest findings on hemp cultivation, processing, materials science, biomedical applications, and regulatory science from PubMed, OpenAlex, and other indexed sources.
This research lays the groundwork for exploring effective add-on compounds to clobazam and valproic acid in treating Dravet syndrome. The study further highlights the utility of the Scn1a<sup>A1783V/WT</sup> mice in discovering therapies for Dravet syndrome-associated pharmacoresistant seizures.
Background: Herbal remedies are making waves in many neurological conditions, and it will be wrong to assume that they do not have to be subjected to the same rigorous ethical investigational pathways as for the synthetic medicines/remedies. The primary and most important concern of pharmacologists in the team of drug developers is the safety of the remedy, whether herbal or synthetic. The remedies are aimed at the human body for the alleviation of the medical condition, so it makes sense to pro
Peer-reviewed industrial hemp research by Katsuhiro Kobayashi; Takashi Shibata; Hiroki Tsuchiya; Mari Akiyama; Tomoyuki Akiyama published in Brain and Development (2025).
The ongoing study has gathered evidence indicating that the injection of barbaloin has resulted in significant improvements in cognitive performance in rats. This is achieved by inhibiting oxidative stress, enhancing the activity of natural antioxidant enzymes, reducing cytokine levels, and increasing the levels of neurotransmitters in the brain. These results were detected in comparison to a PTZ control and can be attributed to the potent anti-inflammatory and antioxidant capabilities of barbal
Most adults with <i>CHD2</i> continue to have seizures, and seizure severity is associated with worse comorbidities such as maladaptive behaviors, gait, gastrointestinal, sleep, and abnormal pain responsiveness. Longevity has not been systematically studied in this group of patients. Here we describe a group of adult patients (up to 45 years of age) and the natural history of this condition. These data may provide prognostic insights for families of pediatric patients and help identify key point
Adults with new epilepsy are frequent users of acute care. There remain a proportion of persons with epilepsy prescribed ASMs that guidelines suggest avoiding, and these ASMs are associated with increased likelihood of emergency department visit or hospitalization. These findings reinforce the importance of optimizing the choice of first ASM in epilepsy.
Zusammenfassung Hintergrund Aktuell werden in der Epileptologie fast ausschließlich Medikamente eingesetzt, die gegen Anfälle wirken („Antikonvulsiva“). Diese beeinflussen die Pathophysiologie der individuell zugrunde liegenden Epilepsie wenig spezifisch im Sinne von „Antiepileptika“. Darauf zielt aber der Begriff „molekulare Pädiatrie“ ab. Methodik Ein großes internationales Netzwerk zum einfachen Erfahrungsaustausch von Klinikern über die Therapie von Kindern mit sehr seltenen genetischen Epil
Cannabidiol (CBD) has gained a lot of interest in recent years for its purported medicinal properties. CBD has been investigated for the treatment of anxiety, depression, epilepsy, neuroinflammation, and pain. Recently there has been an interest in CBD as a possible treatment for age-related disorders such as Alzheimer's disease and related disorders (ADRD). Here we tested the hypothesis that chronic CBD administration would improve learning and memory in the SAMP8 mouse model of Alzheimer's dis
Abstract Introduction Seizure in children with the prevalence of 4 to 6 cases in 1000 is the most common neurological disorder in pediatrics. This study aimed to determine the causes of seizures in children admitted to Kerman hospitals in 2017 Materials and methods In this retrospective study, 250 hospitalized children suffering from seizure were selected through census method. Data collection tool was a checklist. The obtained data was analyzed employing SPSS 24 software, using chi-square, and
Peer-reviewed industrial hemp research by Connie Cameron; Yaron Finkelstein; Karen Leslie published in Paediatrics & Child Health (2020).
This study reveals a high prevalence of marijuana use among patients with epilepsy living in Canada particularly when seizures are drug resistant. A significant proportion of patients reported improvement of seizures with marijuana use, consistent with previous studies. With the increased accessibility of marijuana, it is imperative that physicians are aware of marijuana usage habits among patients with epilepsy.
The high incidence of SC-CIP in our cohort of patients with FIRES suggests a link between these two rare conditions, likely related to prolonged intensive care, hyperinflammation and polytherapy, including ketamine use. Vigilant monitoring of liver disease progression in critically ill patients with FIRES and similar predisposing factors may allow early recognition of SC-CIP and improved patient outcomes.
ClinicalTrials.gov, identifier NCT05374824.
US physicians and medical trainees perceived significant knowledge barriers to recommending MC and counseling patients on its therapeutic use. Implementing clear clinical practice guidelines, further education on these drugs in clinical curriculums, and enhancing continuing education offerings would improve prescriber confidence. Increased research could also assist medical professionals in appropriate clinical decision making.
Epilepsy has a peak incidence during the neonatal to early childhood period. These early onset epilepsies may be severe conditions frequently associated with comorbidities such as developmental deficits and intellectual disability and, in a significant percentage of patients, may be medication-resistant. The use of adult rodent models in the exploration of mechanisms and treatments for early life epilepsies is challenging, as it ignores significant age-specific developmental differences. More re
We developed a focused series of original phenyl-glycinamide derivatives which showed potent activity across <i>in vivo</i> mouse seizure models, namely, maximal electroshock (MES) and 6 Hz (using both 32 and 44 mA current intensities) seizure models. Following intraperitoneal (<i>i.p</i>.) administration, compound <b>(</b><b><i>R</i></b><b>)-32</b>, which was identified as a lead molecule, demonstrated potent protection against all seizure models with ED<sub>50</sub> values of 73.9 mg/kg (MES t
Before widespread prohibition, cannabis and cannabis products had been used in the treatment of epilepsy and seizures with evidence for use stretching back millennia. In recent years, there has been growing evidence that cannabis products have anti-seizure properties, with particular interest on the nonpsychoactive components of cannabis such as cannabidiol (CBD). Indeed, a highly purified form of CBD (Epidiolex®/Epidyolex®) received regulatory approval for the treatment of the severe childhood
Dravet syndrome (DS), previously known as severe myoclonic epilepsy of infancy, is a severe epileptic syndrome affecting children, with an incidence of 1/22,000 to 1/49,900 live births annually. Characterized by resistant and prolonged seizures, it often leads to intellectual impairment, with males being twice as susceptible as females. Its clinical features include recurrent seizures triggered by fever initially, but later occurring spontaneously, developmental delays, behavioral issues, and mo
Increasing awareness around transition readiness is essential to promote self-management skills of patients with epilepsy and their parents. Anticipating the period of transition could be beneficial, especially to prevent problematic sleep patterns and promote independence in health care management. Parents of patients with epilepsy and rare diseases should be monitored for their mental status which can affect patients' well-being.
Peer-reviewed industrial hemp research by Joan Devin; Fergal O’Shaughnessy; M K Sardana; Brian Cleary; Jennifer Donnelly; N Maher published in Epilepsy & Behavior Reports (2025).
Our study revealed unfavorable outcomes for patients with SCN1A variants. Some patients with SCN1A channelopathy showed specific responsiveness to the pharmacotherapies previously either recommended or contraindicated for these patients. Our study also expands the genotype and provides valuable prognostic insights in patients with SCN1A channelopathy.
Peer-reviewed industrial hemp research by Jenna Sahli; Daniel H. Grossoehme; Sarah Friebert published in Journal of Pain and Symptom Management (2024).
Since Guthrie's pioneering work in 1963 on phenylketonuria, the spectrum of diseases addressed in neonatal screening programs has broadened. Ethical considerations regarding the conditions qualifying for neonatal screening were raised as early as the 1960s.1, 2 In 1968, the World Health Organization established recommendations for identifying disease candidates that could benefit from such an approach.3 The main criteria outlined in this report include the importance of the impact of the disease
Peer-reviewed industrial hemp research by Jianxing Zhou; Zhenhui Chen; Mengjun Zhang; Yanrong Ye; Yun Shen; Xuemei Wu published in Seizure (2024).
Bexicaserin was well tolerated and associated with clinically relevant reductions in countable motor seizure frequencies in participants with a variety of DEEs. This novel trial design may expand treatment access to patients previously excluded from clinical trials.